🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT04689854
Enrolling by invitation Observational

Cervical Interbody Implant Study

NCT04689854 · tracked via the Priya Life Science USA tracker
Sponsor
NuVasive
Phase
Observational
Started
2020-07-07
Last updated
2025-12-22

Condition(s) studied

Degenerative Disc DiseaseCervical Spinal Instability

Study summary

The primary objective of this study is to evaluate the safety and performance of cervical spine surgery using interbody implants as measured by reported complications, radiographic outcomes, and patient-reported outcomes (PROs).

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: 1. Patients who are ≥18 years of age at the time of consent 2. Have a planned spine surgery using interbody implants at one or more cervical levels (C2-T1) for degenerative disc disease and/or cervical spinal instability 3. Using one of the following implants (NuVasive, Inc., San Diego, CA): 1. Cohere Cervical 2. Modulus Cervical 4. With interbody fusion using autograft and/or allograft (i.e., cancellous and/or corticocancellous allograft bone) and NuVasive supplemental internal fixation cleared by the applicable regulatory body for use in the cervical spine 5. Able to undergo surgery based on physical exam, medical history, and surgeon judgment 6. Understands the conditions of enrollment, is willing to follow medical advice including postoperative activity restrictions per the surgeon's standard of care, and is willing to sign an informed consent form to participate in the study Exclusion Criteria: 1. Use of any bone graft that is not cleared by the applicable regulatory body for use within interbody implants. Examples of these include: 1. Bone morphogenic protein (BMP) (i.e., Infuse (Medtronic)) 2. Synthetic bone graft extenders (e.g., Formagraft (NuVasive), Mastergraft (Medtronic), Vitoss (Stryker), Actifuse (Baxter), nanOss (RTI Surgical), Fibergraft (Prosidyan/Depuy Synthes), and ChronOs (Depuy Synthes)) 3. Demineralized bone matrices (DBM) regulated as medical devices by the FDA (e.g., Grafton Putty/Gel (Medtronic), DBX (MTF/Depuy Synthes), Accell Evo3 (IsoTis), and Propel Putty/Gel (NuVasive)) 4. Peptide enhanced bone graft (e.g., iFactor (Cerapedics)) 2. Previous cervical fusion surgery at the level(s) to be treated (adjacent level surgery is acceptable; prior decompression is acceptable) 3. Patient is involved in active litigation relating to the spine (worker's compensation claim is allowed if it is not contested) 4. Use of bone growth stimulators postoperatively 5. Active smoking within 6 weeks before surgery 6. Patient has known sensitivity to the materials implanted 7. Systemic or local infection (latent or active) or signs of local inflammation 8. Patient has inadequate bone stock or bone quality, or a physical or medical condition that would prohibit beneficial surgical outcome based on surgeon judgment 9. Patient is a prisoner 10. Patient is participating in another clinical study that would confound study data

Primary outcome measure(s)

Trial sites (7)

FacilityCityRegionStatus
Orthopedic Specialty Institute Orange California
Hartford Healthcare Bone and Joint Institute Hartford Connecticut
Mass General Brigham Somerville Massachusetts
Columbia Orthopedic Group Research Columbia Missouri
Duke University Durham North Carolina
Summa Health Akron Ohio
University of Virginia Charlottesville Virginia

More NuVasive trials in the USA

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04689854 on ClinicalTrials.gov ↗ ← All trials in the USA